Figure 4.
tAML-related prognostic factors. (A) Probability of OS and EFS stratified by risk-related factors in pediatric tAML compared with de novo AML diagnosed from 2004. The median follow-up was 10.9 years for OS (95% CI, 10.2-11.5) and 10.5 years for EFS (95% CI, 9.9-11.2). (B) Forest plots of multivariate proportional hazards models for OS and EFS in pediatric tAML. Latency ≤1 year to tAML; cytogenetic risk encompassed –7/del(7q), monosomy, and complex karyotype; HSCT NEL is morphologically defined as <5% blasts and no extramedullary blasts. AML-HR, high-risk assignment according to the corresponding AML-BFM protocol; KMT2Ar, lysine methyltransferase 2A rearrangement.

tAML-related prognostic factors. (A) Probability of OS and EFS stratified by risk-related factors in pediatric tAML compared with de novo AML diagnosed from 2004. The median follow-up was 10.9 years for OS (95% CI, 10.2-11.5) and 10.5 years for EFS (95% CI, 9.9-11.2). (B) Forest plots of multivariate proportional hazards models for OS and EFS in pediatric tAML. Latency ≤1 year to tAML; cytogenetic risk encompassed –7/del(7q), monosomy, and complex karyotype; HSCT NEL is morphologically defined as <5% blasts and no extramedullary blasts. AML-HR, high-risk assignment according to the corresponding AML-BFM protocol; KMT2Ar, lysine methyltransferase 2A rearrangement.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal